Diapharm Analytics extends its BtM license to include cannabis

Oldenburg, 25.03.2019 (PresseBox) – The GMP-certified contract laboratory Diapharm Analytics has expanded its narcotics license to include cannabis. In the future, we can offer our customers the analytics according to the current DAB monograph “Cannabis Flos”. These are the analytical parameters of identity, content and purity. The specifications of the Ph. Eur. Monograph “herbal drugs” including the analysis of pesticides, heavy metals, aflatoxins and microbiological purity can also be investigated.
The medical cannabis market is undergoing rapid changes. Worldwide regulatory changes and numerous new developments in medical cannabis products are leading to a growing need for highly professional services. Diapharm, the leading consultant and service provider for strategic solutions, regulatory and QM tasks, and the laboratory Diapharm Analytics, a Tentamus company, are happy to support you in the realization of your cannabis projects.
As a member of the Tentamus Group, Diapharm Analytics offers an all-round service in cooperation with our partner laboratories. These include:
Cannabis flos
batch release testing
Stability studies
Clinical studies
New Formulations of cannabis flos:
Method development and method validation
Analysis and monitoring of product development
Stability studies
Clinical studies
 
In the run-up, Diapharm can provide strategic, regulatory and QM consulting. We can prepare all documents and manage all necessary processes to establish our clients as importers (2001/83/EC Art. 40 et seqq.) and/or wholesale distributors (Art. 76 et seqq.) with a licence pursuant to the German Narcotic Drugs Act (BTMG) for medical cannabis. Contact us!
 

Ersten Kommentar schreiben

Antworten

Deine E-Mail-Adresse wird nicht veröffentlicht.


*